ADMA Biologics (NASDAQ:ADMA) Announces Quarterly Earnings Results

ADMA Biologics (NASDAQ:ADMA) released its quarterly earnings data on Thursday. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03, Briefing.com reports. The company had revenue of $81.90 million during the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The firm’s revenue was up 43.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. ADMA Biologics updated its FY 2024 guidance to EPS and its FY 2025 guidance to EPS.

ADMA Biologics Price Performance

Shares of ADMA stock traded up $1.88 during trading hours on Friday, reaching $8.81. The company had a trading volume of 8,192,347 shares, compared to its average volume of 2,649,495. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16. The stock has a fifty day moving average of $6.33 and a 200-day moving average of $5.09. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -67.77 and a beta of 0.43. ADMA Biologics has a 12-month low of $3.06 and a 12-month high of $8.85.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ADMA. HC Wainwright raised their target price on ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald upped their target price on ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday. Raymond James increased their target price on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday. Finally, Mizuho increased their target price on ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $10.50.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $6.01, for a total transaction of $1,099,878.08. Following the transaction, the director now owns 2,577,387 shares of the company’s stock, valued at $15,490,095.87. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 639,895 shares of company stock worth $3,927,169. Company insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.